ライフサイエンスコーパス: euglycemic hyperinsulinemic clamp

1 nd hepatic glucose production as assessed by euglycemic hyperinsulinemic clamp.

2 althy, young male subjects was determined by euglycemic hyperinsulinemic clamp.

3 ipid or glycerol (control), rats underwent a euglycemic hyperinsulinemic clamp.

4 zed in vivo using indirect calorimetry and a euglycemic hyperinsulinemic clamp.

5 ured by both oral glucose tolerance test and euglycemic-hyperinsulinemic clamp.

6 insulin sensitivity was quantitated with the euglycemic-hyperinsulinemic clamp.

7 travenous glucose tolerance test (IVGTT) and euglycemic-hyperinsulinemic clamp.

8 lucose production is impaired as assessed by euglycemic-hyperinsulinemic clamp.

9 as compared before and during AICAR with the euglycemic-hyperinsulinemic clamp.

10 out (n = 34) a family history of diabetes by euglycemic-hyperinsulinemic clamp.

11 Fifty-eight subjects also received a euglycemic-hyperinsulinemic clamp.

12 o induce insulin resistance in rats during a euglycemic-hyperinsulinemic clamp.

13 atic insulin resistance, as verified using a euglycemic/hyperinsulinemic clamp.

14 alysis with oral glucose tolerance tests and euglycemic-hyperinsulinemic clamps.

15 asured in SU and SU + MET rats by performing euglycemic-hyperinsulinemic clamps.

16 TIMPs]) in aortic tissue of male rats during euglycemic-hyperinsulinemic clamping.

17 lthy nonobese male volunteers using two-step euglycemic-hyperinsulinemic clamps (2 h at 16.6 micro g

18 Here we show that initiation of a euglycemic-hyperinsulinemic clamp 4 h after single-legge

19 and the other with insulin (0.03 U/kg) and a euglycemic hyperinsulinemic clamp (40 mU x m(-2) x min(-

20 eride content of the soleus muscle, 2) a 2-h euglycemic-hyperinsulinemic clamp (40 mU.m(-2).min(-1))

21 measurements before and at the end of a 3-h euglycemic-hyperinsulinemic clamp (40 or 240 mU x min(-1

22 of disappearance [G(R)(d)], determined using euglycemic-hyperinsulinemic clamp) 442% (P < 0.01), oral

23 educed insulin resistance, measured with the euglycemic hyperinsulinemic clamp, along with the ratio

24 The OG-CLAMP method combines a euglycemic, hyperinsulinemic clamp and an oral glucose t

25 hin skeletal muscle of an awake rat during a euglycemic-hyperinsulinemic clamp and increased levels o

26 A euglycemic-hyperinsulinemic clamp and skeletal muscle bi

27 glucose metabolism (insulin tolerance test, euglycemic-hyperinsulinemic clamp, and hepatic expressio

28 the basal state and during 240 pmol/m(2)/min euglycemic-hyperinsulinemic clamp, and liver (LF) subcut

29 ripheral insulin sensitivity was analyzed by euglycemic-hyperinsulinemic clamp, and molecular tools w

30 gated the association of genetic scores with euglycemic-hyperinsulinemic clamp- and oral glucose tole

31 ese, and type 2 subjects before and after an euglycemic-hyperinsulinemic clamp as well as pre-and pos

32 ulated by insulin in vivo in mice undergoing euglycemic-hyperinsulinemic clamps, being highly up-regu

33 ence in change in IR assessed using a 2-step euglycemic-hyperinsulinemic clamp combined with infusion

34 ; P = 0.21), or glucose disposal rates under euglycemic hyperinsulinemic clamp conditions (SMD: 0.00;

35 Under euglycemic- hyperinsulinemic clamp conditions, indinavir

36 is of glucose homeostasis was assessed using euglycemic-hyperinsulinemic clamp coupled with tracer ra

37 er, insulin stimulation during a 100-140-min euglycemic/hyperinsulinemic clamp did not result in any

38 SI was measured using euglycemic-hyperinsulinemic clamp (EGC), before (week 0

39 In this prospective study, euglycemic hyperinsulinemic clamp (EHC) was performed at

40 ere studied before and 1 month after RYGB by euglycemic hyperinsulinemic clamp (EHC), by intravenous

41 Euglycemic-hyperinsulinemic clamp (EHC) was preformed to

42 Euglycemic-hyperinsulinemic-clamp experiments further de

43 nges in glucose-6-phosphate (G-6-P) during a euglycemic-hyperinsulinemic clamp in awake Zucker fatty

44 was investigated in normal volunteers during euglycemic-hyperinsulinemic clamping in which plasma fre

45 se transport in muscle biopsies taken during euglycemic-hyperinsulinemic clamps in nondiabetic, obese

46 Euglycemic, hyperinsulinemic clamp (insulin clamp, n=8)

47 nsulin clamp method: subjects received a 7-h euglycemic-hyperinsulinemic clamp (insulin infusion rate

48 emulsion (liposyn) infusion during a 120-min euglycemic-hyperinsulinemic clamp led to significant red

49 This study using the euglycemic-hyperinsulinemic clamp method was performed i

50 A euglycemic-hyperinsulinemic clamp, muscle biopsy specime

51 Thirty patients at risk for CIM underwent euglycemic-hyperinsulinemic clamp, muscle microdialysis

52 s with infusion of saline alone (n = 16) and euglycemic-hyperinsulinemic clamps (n = 10, serum insuli

53 estigate this, eight healthy men underwent a euglycemic-hyperinsulinemic clamp on 2 separate days: on

54 ct of physiological hyperinsulinemia (during euglycemic-hyperinsulinemic clamping) on free fatty acid

55 and 4 h after lowering of plasma FFAs (with euglycemic-hyperinsulinemic clamping) or after increasin

56 Subjects were also studied by euglycemic-hyperinsulinemic clamps performed at rest and

57 skeletal muscle, and adipose tissue (with a euglycemic-hyperinsulinemic clamp procedure and isotope-

58 A euglycemic-hyperinsulinemic clamp procedure and stable i

59 Stable isotope tracer techniques and the euglycemic-hyperinsulinemic clamp procedure were used to

60 10 with normal glucose tolerance) using the euglycemic-hyperinsulinemic clamp procedure, before preg

61 trates that infusion of glucosamine during a euglycemic-hyperinsulinemic clamp results in marked accu

62 The effect of eritoran was assessed with euglycemic hyperinsulinemic clamps.ResultsIn protocol I,

63 Fetuin KO mice subjected to euglycemic-hyperinsulinemic clamp show augmented sensiti

64 nondiabetic patients, 135 of whom underwent euglycemic-hyperinsulinemic clamps, showed that subjects

65 by isotope dilution, insulin sensitivity by euglycemic-hyperinsulinemic clamp (steady-state glucose

66 in vivo hepatic insulin action, we performed euglycemic hyperinsulinemic clamp studies in conscious L

67 Euglycemic hyperinsulinemic clamp studies were performed

68 Euglycemic, hyperinsulinemic clamp studies indicated RYG

69 stered for 30, 60, 90, or 120 min during 2-h euglycemic, hyperinsulinemic clamp studies.

70 Euglycemic-hyperinsulinemic clamp studies (12 mU x kg(-1

71 Euglycemic-hyperinsulinemic clamp studies confirmed the

72 Euglycemic-hyperinsulinemic clamp studies demonstrate th

73 re assessed before (basal period) and during euglycemic-hyperinsulinemic clamp studies.

74 n PAI-1(-/-) mice on an HF diet, as shown by euglycemic-hyperinsulinemic clamp studies.

75 ications (EDC) Study and was validated using euglycemic-hyperinsulinemic clamp studies.

76 edly enhanced glucose uptake measured during euglycemic-hyperinsulinemic clamps, suggesting a role of

77 nt measurement of insulin sensitivity by the euglycemic hyperinsulinemic clamp technique (soluble ins

78 seline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique.

79 insulin action were assessed by means of the euglycemic hyperinsulinemic clamp technique.

80 In vivo insulin action was measured by the euglycemic-hyperinsulinemic clamp technique at a submaxi

81 was measured in 26 healthy adults using the euglycemic-hyperinsulinemic clamp technique to achieve a

82 ects for insulin sensitivity (measured using euglycemic-hyperinsulinemic clamp technique with [3-3H]g

83 dy insulin sensitivity, as determined by the euglycemic-hyperinsulinemic clamp technique, was signifi

84 onfirmed in both males and females using the euglycemic-hyperinsulinemic clamp technique; glucose dis

85 The next day a euglycemic hyperinsulinemic clamp test was administered.

86 Insulin sensitivity measured by euglycemic hyperinsulinemic clamp testing; subcutaneous

87 Furthermore, during an euglycemic hyperinsulinemic clamp, the glucose infusion

88 During euglycemic-hyperinsulinemic clamp, there is no suppressi

89 lin-stimulated glucose uptake as measured by euglycemic-hyperinsulinemic clamps throughout the course

90 of pancreas transplants, we devised a staged euglycemic hyperinsulinemic clamp to measure hepatic glu

91 entions, we conducted a meal challenge and a euglycemic-hyperinsulinemic clamp to evaluate insulin se

92 In this study, a euglycemic hyperinsulinemic clamp was performed on obese

93 extensor digitorum longus muscle during the euglycemic-hyperinsulinemic clamp was increased in lean

94 when plasma FFA levels were elevated during euglycemic-hyperinsulinemic clamping was associated with

95 tion (a measure of NO bioavailability) after euglycemic-hyperinsulinemic clamp were blunted in the ao

96 etabolism was measured by real-time PCR, and euglycemic-hyperinsulinemic clamps were used for insulin

97 3.6 years) pre- and 3 months post-RYGB, and euglycemic-hyperinsulinemic clamps were used to assess i

98 During the euglycemic hyperinsulinemic clamp, whole body glucose di

99 ty in liver, muscle, and adipose tissue by a euglycemic hyperinsulinemic clamp with 3-(3)H-glucose.

100 , whole-body and muscle insulin sensitivity (euglycemic-hyperinsulinemic clamp with 2-deoxyglucose) a

101 on insulin sensitivity, as measured by using euglycemic-hyperinsulinemic clamps with infusion of [6,6

102 Four-hour euglycemic-hyperinsulinemic clamps with infusion of sali

103 in-resistant subjects (n = 10 each) received euglycemic-hyperinsulinemic clamps with muscle biopsies